Anika Therapeutics, Inc. (ANIK) Form 8-K — Apr 29, 2026
Anika Therapeutics reported financial results for the first quarter ended March 31, 2026, with total revenue growing 13% year-over-year to $29.6 million. This growth was driven by strength across both the OEM and Commercial channels, with the Commercial Channel seeing a 20% increase in Regenerative Solutions revenue. The company achieved a significant improvement in profitability, delivering adjusted EBITDA of $4.3 million compared to $0.1 million in the prior-year period, fueled by an 810 basis point expansion in gross margin to 64.2%.
Key figures
- Guidance
- Total Company Revenue between $114 and $122.5 million; Commercial Channel $53 to $58 million; OEM Channel $61 to $64.5 million; Adjusted EBITDA as a percent of revenue between 5% and 10%
- Revenue Yoy
- 13%
- Adjusted EBITDA
- 4300000
- Integrity Revenue
- 1800000
- Operating Expenses
- 24500000
- Gross Margin Percent
- 64.2%
- Share Repurchase Amount
- 15000000
- Share Repurchase Avg Price
- 10.76
- Commercial Channel Revenue
- 12600000
- Integrity Procedure Growth
- 35%
- Adjusted EBITDAMargin Percent
- 14.5%
Price after filing
Close on the filing date to close N calendar days later (from $12.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.